Phase 1/2 Open-Label Trial to Assess the Safety and Preliminary Efficacy of 177Lu-OPS201 as Peptide Receptor Radionuclide Therapy in Patients With Somatostatin Receptor-Positive, Progressive Neuroendocrine Tumors

被引：0
|
作者：
Nicolas, Guillaume [1 ,2 ]
Bodei, Lisa [3 ]
Baum, Richard [4 ]
Herrmann, Ken [5 ]
Lassmann, Michael [6 ]
Hicks, Rodney [7 ]
Navalkissoor, Shaunak [2 ]
Haug, Alexander [8 ]
Oberwittler, Heike [9 ]
Wang, Tiffany [10 ]
Wild, Damian [1 ]
机构：
[1] Univ Basel Hosp, Basel, Switzerland
[2] Royal Free Hosp, London, England
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Zent Klin Bad Berka, Bad Berka, Germany
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Hosp Wurzburg, Wurzburg, Germany
[7] Peter MacCallum Canc Ctr, East Melbourne, Australia
[8] Med Univ Vienna, Vienna, Austria
[9] Ipsen, Les Ulis, France
[10] Ipsen, Cambridge, MA USA
来源：
PANCREAS | 2018年 / 47卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [31] A phase I trial of Triapine and Lutetium Lu 177 Dotatate in combination for well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Chauhan, Aman
    Kunos, Charles
    El Khouli, Riham
    Kolesar, Jill
    Weiss, Heidi L.
    Carson, Bill
    Kidd, Mark
    Beumer, Jan
    Arnold, Susanne
    Kohn, Elise
    Anthony, Lowell
    CANCER RESEARCH, 2021, 81 (13)
  • [32] Efficacy of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Inoperable/Metastatic, Progressing Neuroendocrine Tumors: Results of Our First Clinical Experience
    Gunalp, B.
    Ucgun, A.
    Goker, U.
    Mahmudov, S.
    Ince, S.
    Alagoz, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S641 - S642
  • [33] Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Chauhan, Aman
    Kunos, Charles
    El Khouli, Riham
    Kolesar, Jill
    Weiss, Heidi
    Carson, William Edgar
    Evers, Mark B.
    Kidd, Mark S.
    Beumer, Jan Hendrik
    Arnold, Susanne M.
    Kohn, Elise C.
    Anthony, Lowell Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs)
    Chauhan, Aman
    Arnold, Susanne
    Kolesar, Jill
    Carson, William
    Weiss, Heidi
    Jayswal, Rani
    Yan, Donglin
    El Khouli, Riham
    Khurana, Aman
    Beumer, Jan
    Soares, Heloisa
    Mulcahy, Mary
    Halfdanarson, Thorvardur
    Li, Daneng
    Jacene, Heather
    Ivy, Percy
    Kohn, Elise
    Wright, John
    Rubinstein, Larry
    Chow, Zeta
    Rychahou, Piotr
    Evers, Mark B.
    Kunos, Charles
    Anthony, Lowell
    Konda, Bhavana
    CANCER RESEARCH, 2023, 83 (08)
  • [35] Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    Hoersch, D.
    Prasad, V.
    Baum, R. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1,000 Patients from a Single Center
    Baum, R. P.
    Kulkarni, H.
    Zachert, C.
    Kaemmerer, D.
    Petrovitch, A.
    Niepsch, K.
    Hommann, M.
    Hoersch, D.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 282 - 282
  • [37] 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: A real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center.
    Nalder, Mark
    Ladwa, Rahul
    Raina, Anant
    Burge, Matthew E.
    Love, Amanda
    Pattison, David A.
    Ramsay, Stuart
    Wyld, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Results from OCLURANDOM: the first multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with lutetium-177 octreotate (OCLU) in patients with unresectable progressive neuroendocrine pancreatic tumors
    Baudin, E.
    Walter, T.
    Beron, A.
    Smith, D.
    Hadoux, J.
    Moreau-Triby, C.
    Taieb, D.
    Ansquer, C.
    Dierickx, L.
    De Mestier, L.
    Deshayes, E.
    Quak, E.
    Dahan, L.
    Guimbaud, R.
    Touchefeu, Y.
    Haissaguerre, M.
    Vuillez, J.
    Courbon, F.
    Hindie, E.
    Do Cao, C.
    Lombard-Bohas, C.
    Attard, M.
    Foulon, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S52 - S52
  • [39] Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial
    Heudel, Pierre
    Frenel, Jean-Sebastien
    Dalban, Cecile
    Bazan, Fernando
    Joly, Florence
    Arnaud, Antoine
    Abdeddaim, Cyril
    Chevalier-Place, Annick
    Augereau, Paule
    Pautier, Patricia
    Chakiba, Camille
    You, Benoit
    Lancry-Lecomte, Laurence
    Garin, Gwenaelle
    Marcel, Virginie
    Diaz, Jean Jacques
    Treilleux, Isabelle
    Perol, David
    Fabbro, Michel
    Ray-Coquard, Isabelle
    JAMA ONCOLOGY, 2022, 8 (07) : 1001 - 1009
  • [40] A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)
    Partelli, S.
    Landoni, L.
    Bartolomei, M.
    Zerbi, A.
    Grana, C. M.
    Boggi, U.
    Butturini, G.
    Casadei, R.
    Bassi, C.
    Falconi, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S703 - S703
12345